Health
MEI Pharma Reports Preclinical Data Demonstrating Ability of Voruciclib to Regulate MYC and Synergize with KRAS Inhibitors in KRAS Mutant Cancers – StreetInsider.com
SAN DIEGO, April 10, 2021 /PRNewswire/ — MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer,…
SAN DIEGO, April 10, 2021 /PRNewswire/ — MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced preclinical data demonstrating that voruciclib, an orally administered cyclin-dependent kinase (CDK) inhibitor that is potent against CDK9, has single agent activity against multiple KRAS mutant cancer cell lines and synergistically inhibits growth of KRAS mutant cancers in combination with KRAS inhibitors. The research is…
-
General21 hours agoGymnastics club in Berwick shuts down following child safety complaint
-
General15 hours agoAshes engulfed by fresh DRS controversy as TV umpire gives Jamie Smith out despite RTS ‘murmur’
-
General18 hours ago‘Mother’s Day’ solar storm squeezed Earth’s plasmasphere to one-fifth its size
-
Noosa News23 hours agoAmazing mating behaviour of our local fauna